Solitary Pulmonary Nodule Clinical Trial
Official title:
Evaluation of Lung Nodule and Lung Cancer Detection With Artificial Intelligence Assisted Computed Tomography Among People Living in North China: a Prospective Single-arm Multicentre Study of Screening
Lung cancer is one of the leading cause of cancer related death in China. Lung cancer
screening with low-dose computed tomography was considered as a better approach than
radiography. However, the role of Lung cancer screening with Low-dose CT (LDCT) among Chinese
people remains unclear. With rapid development of artificial intelligence (AI),the
application of AI in detection and diagnosis of diseases has become research focus. Moreover,
patients' psychological status also plays an important role in diagnosis and treatment.
This study focuses on detection and natural history management of lung nodule and lung cancer
with AI assisted chest CT among people living in North China, and aims to investigate
epidemiological results, patients' medical records and social psychological status.
Status | Not yet recruiting |
Enrollment | 5000 |
Est. completion date | December 2021 |
Est. primary completion date | December 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years and older |
Eligibility |
Inclusion Criteria: - Aged 40 years or older - Routinely conducting chest CT scan at a low-dose setting (120kVp, 40-80mA, slice thickness of 1.25 mm or less) yearly in Lu'an Municipal Hospital and North China Petroleum Bureau General Hospital in at least the past 4 years up to December 2017, willing to continue routine yearly LDCT scan. - Chest CT data are available for DICOM format. - Signed Informed Consent Form. Exclusion Criteria: - Pregnant woman and the disabled - Past thoracic surgery history, except for diagnostic thoracoscopy - Poor physical status without sufficient respiratory reserve to undergo lobectomy if necessary - Shortened life expectancy less than 10 years - Malignant tumor history within the past 5 years, except for the following conditions: cured skin basal cell carcinoma, superficial bladder carcinoma. and uterine cervix cancer in situ. - Past history of interstitial lung disease, pulmonary bulla and lung tuberculosis. - Other circumstances which is deemed inappropriate for enrollment by the researchers. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Peking University People's Hospital | Lu'an Municipal Hospital, North China Petroleum Bureau General Hospital |
Baldwin DR, Callister ME; Guideline Development Group. The British Thoracic Society guidelines on the investigation and management of pulmonary nodules. Thorax. 2015 Aug;70(8):794-8. doi: 10.1136/thoraxjnl-2015-207221. Epub 2015 Jul 1. Review. — View Citation
Detterbeck FC, Mazzone PJ, Naidich DP, Bach PB. Screening for lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May;143(5 Suppl):e78S-e92S. doi: 10.1378/chest.12-2350. Review. — View Citation
Field JK, Oudkerk M, Pedersen JH, Duffy SW. Prospects for population screening and diagnosis of lung cancer. Lancet. 2013 Aug 24;382(9893):732-41. doi: 10.1016/S0140-6736(13)61614-1. Review. — View Citation
Harris RP, Sheridan SL, Lewis CL, Barclay C, Vu MB, Kistler CE, Golin CE, DeFrank JT, Brewer NT. The harms of screening: a proposed taxonomy and application to lung cancer screening. JAMA Intern Med. 2014 Feb 1;174(2):281-5. doi: 10.1001/jamainternmed.2013.12745. Review. Erratum in: JAMA Intern Med. 2014 Mar;174(3):484. — View Citation
National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011 Aug 4;365(5):395-409. doi: 10.1056/NEJMoa1102873. Epub 2011 Jun 29. — View Citation
Silva M, Pastorino U, Sverzellati N. Lung cancer screening with low-dose CT in Europe: strength and weakness of diverse independent screening trials. Clin Radiol. 2017 May;72(5):389-400. doi: 10.1016/j.crad.2016.12.021. Epub 2017 Feb 4. Review. — View Citation
Wiener RS, Gould MK, Woloshin S, Schwartz LM, Clark JA. What do you mean, a spot?: A qualitative analysis of patients' reactions to discussions with their physicians about pulmonary nodules. Chest. 2013 Mar;143(3):672-677. doi: 10.1378/chest.12-1095. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Detection rate of lung nodule | Study participants undergo baseline LDCT. Images are reviewed via AI software independently to identify lung nodules with diameters greater than 4mm. The software is developed by our computer technology collaborator. A radiologist then reviews the images, reports lung nodules with diameters greater than 4mm and any other abnormalities. The radiologist's findings will be conveyed to the study participants or their primary care physicians within 3 weeks. The process was conducted via double-blind method and detection rates of AI and radiologist will be recorded respectively. Unit of measurement: Percentage (number of participants with detected lung nodules over the total number of participants). | 3 months | |
Primary | Profile of detected lung nodule | All lung nodules detected will be classified as 4 classes by the density and composition of nodule: 1. pure ground-glass nodule (pGGN); 2. part-solid nodule; 3. solid nodule; 4. uncertain nodule. The number and proportion of each class and the diameter and location of each nodule will be recorded. Unit of measurement: Percentage (number of nodules in each class over the total number of nodules); Numerical value (average value±standard deviation of nodules in each class); Percentage (number of nodules in each lobe over the total number of nodules). | 3 months | |
Secondary | Sensitivity in the detection of clinically actionable lung nodules | AI assisted CT compared with conventional CT read via radiologist. Unit of measurement: Percentage (detected actionable lung nodules over the total number of actionable nodules). | 3 months | |
Secondary | Growth of lung nodule | Study participants undergo baseline LDCT and subsequent yearly LDCT. Making use of these consecutive CT images, volume doubling time (VDT) for each lung nodule can be calculated via software and can be used to evaluate growth of nodule. cUnit of measurement: Numerical value (volume doubling time, VDT). | 3 years | |
Secondary | Anxiety and depression level | Hospital Anxiety and Depression Scale (HADS) is included in our questionnaire and score of this scale will be recorded. Unit of measurement: Numerical value (score of scale). | 3 months | |
Secondary | Life quality and health status | The MOS item short from health survey (SF-36) is included in our questionnaire and score of this scale will be recorded. Unit of measurement: Numerical value (score of scale). | 3 months | |
Secondary | Lung cancer detection rate | Percentage (the number of detected lung nodules which was finally diagnosed as primary lung cancer over the total number of detected lung nodules) | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT05066776 -
Liquid Biopsy With PET/CT Versus PET/CT Alone in Diagnosis of Small Lung Nodules
|
||
Completed |
NCT01958931 -
Evaluate the Utility of the ProLung Test as Adjunctive to CT Scan in the Diagnosis of Lung Cancer
|
N/A | |
Recruiting |
NCT03528733 -
Feasibility of Multi-Energy Digital Radiography Detector for Lung Lesions Detection
|
N/A | |
Recruiting |
NCT02693496 -
Mobile Lung Nodule Observatory for Worldwide, Evidenced-based Research
|
||
Completed |
NCT01566682 -
A Multi-Center Trial of the ProLung Test™
|
||
Terminated |
NCT02983903 -
Cryobiopsy Versus Forceps Biopsy for Pulmonary Lesions
|
N/A | |
Terminated |
NCT02050724 -
ThoHSpEkt Thoracoscopic Ectomy of Radioactively Marked Pulmonary Nodules With Free-hand SPECT
|
Phase 2 | |
Not yet recruiting |
NCT04615156 -
18F-2-fluoro-2-deoxy-D-glucose in Positron Emission Tomography Computed Tomography
|
Phase 3 | |
Recruiting |
NCT02726633 -
Evaluate the Utility of the ProLung China Test in the Diagnosis of Lung Cancer
|
N/A | |
Active, not recruiting |
NCT02623712 -
The Watch the Spot Trial
|
N/A | |
Recruiting |
NCT03568799 -
4-[18F]Fluoroglutamine PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules
|
N/A | |
Not yet recruiting |
NCT02817048 -
Tubeless VATS for Peripheral Lung Nodule
|
N/A | |
Recruiting |
NCT01149187 -
Usefulness of Interferon-gamma Release Assay in Diagnosing Pulmonary Nodules
|
N/A | |
Completed |
NCT00925210 -
Bronchoscopic Approach to the Peripheral Lung Nodule - An Alternative Approach
|
Phase 2 | |
Completed |
NCT02448225 -
18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules
|
Phase 2 | |
Active, not recruiting |
NCT05171491 -
LungLB in Subjects Presenting With Indeterminate Pulmonary Nodules
|
||
Terminated |
NCT04140474 -
Evaluation of the Archimedes ™ System for Transparenchymatous Access to Pulmonary Nodules.
|
N/A | |
Withdrawn |
NCT05804435 -
iNod™ Ultrasound-Guided Needle Biopsy System Study
|
N/A | |
Not yet recruiting |
NCT02653859 -
Evaluate the Auxiliary Diagnostic Value of Circulating Tumor Cells in Benign and Malignant Lung Nodules
|
N/A | |
Completed |
NCT02832284 -
iNod System Human Feasibility Assessment
|
N/A |